There are 2185 resources available
1000MO - A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors
Presenter: Kristopher Wentzel
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
1001MO - Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation
Presenter: Martin Wermke
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
CN5 - Journeying through the landscape of home-based pediatric cancer care: Needs and expectations from the insights of children and parents
Presenter: Hazal Özdemir Koyu
Session: SIOPE-EONS collaborative session
Resources:
Abstract
CN16 - Effectiveness of technology-based intervention in symptom management in pediatric oncology patients: A systematic review and meta-analysis
Presenter: Eysan Hanzade Savaş
Session: SIOPE-EONS collaborative session
Resources:
Abstract
1539MO - Oncologists’ voices in time of crisis: Findings from the ESMO Resilience Task Force survey series on how members can be helped and supported – A qualitative analysis
Presenter: Claire Hardy
Session: Mini oral session: Policy and preventive strategies
Resources:
Abstract
66O - Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers
Presenter: Joseph Sacco
Session: Proffered paper session 2: Basic science & Translational research
Resources:
Abstract
1241MO - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study
Presenter: Shun Lu
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
Presenter: Jennifer Chan
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Abstract
1718O - EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)
Presenter: Nicolas Penel
Session: Proffered paper session: Sarcoma
Resources:
Abstract
1540MO - The patient voice: An analysis of real-world data using the recurrent respiratory papillomatosis foundation/CoRDS patient registry (RRPF/CoRDS)
Presenter: Sara Pai
Session: Mini oral session: Policy and preventive strategies
Resources:
Abstract